Skip to main content
SpringerLink
Log in

Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men

  • Original Paper
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

This study was designed to investigate ethnic differences in the pharmacokinetics (PKs) of moxifloxacin and its metabolites, M1 (sulfo conjugate) and M2 (acyl-glucuronate), among Japanese, Chinese, and Korean populations, following oral administration. We used a population PK modeling approach using data from a clinical study involving 79 healthy male volunteers. A comprehensive population PK model considering the PK mechanism of moxifloxacin and its metabolites was newly built. The structures of the final model were two-compartment for moxifloxacin and one-compartment for M1 and M2, with first-order absorption with lag time for all three compounds. The formation of M1 and M2 from moxifloxacin via a first-pass effect and subsequent metabolic clearance in the system were also modeled. Lean body mass on the central volume of distribution (V c ) and estimated glomerular filtration rate on renal clearance (CL r ) were identified as covariates of PKs of moxifloxacin. Additionally, bioavailability was slightly higher in Koreans, whereas CL r , non-renal clearance (CL nr ), and V c were slightly lower. Regarding M1 and M2, body surface area on CL r of M2 and UGT1A1*6 on F of M2 were modeled. Korean ethnicity was observed to influence CL nr of M2, F of M2, and the metabolic clearance of moxifloxacin to M2. However, the exposure levels of moxifloxacin, M1, and M2 in Koreans were comparable to those in Japanese and Chinese because the effects of Korean ethnicity on some PK parameters were counterbalanced. These results suggest that PKs for moxifloxacin and its metabolites among East Asian populations are essentially similar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Mori K, Toyoshima S (2009) Recent approaches by the PMDA to promoting new drug development: change in the status of the PMDA in relation to new drug development over the last five years. Drug Inf J 43:47–55

    Article  Google Scholar 

  2. Fukunaga S, Kusama M, Arnold FL, Ono S (2011) Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan. J Clin Pharmacol 51:1237–1240

    Article  PubMed  Google Scholar 

  3. Nakajima M, Kuroiwa Y, Yokoi T (2002) Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev 34:865–877

    Article  CAS  PubMed  Google Scholar 

  4. Chu KM, Hu OY, Pao LH, Hsiong CH (2007) Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. J Pharm Pharm Sci 10:411–419

    Article  CAS  PubMed  Google Scholar 

  5. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330–341

    Article  CAS  PubMed  Google Scholar 

  6. Yasuda SU, Zhang L, Huang SM (2008) The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 84:417–423

    Article  CAS  PubMed  Google Scholar 

  7. Chuah B, Goh BC, Lee SC, Soong R, Lau F, Mulay M, Dinolfo M, Lim SE, Soo R, Furuie T, Saito K, Zergebel C, Rosen LS (2011) Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 102:478–483

    Article  CAS  PubMed  Google Scholar 

  8. Hasunuma T, Tohkin M, Kaniwa N, Jang IJ, Yimin C, Kaneko M, Saito Y, Takeuchi M, Watanabe H, Yamazoe Y, Uyama Y, Kawai S (2016) Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Br J Clin Pharmacol 81:1078–1090

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Burkhardt O, Welte T (2009) 10 years’ experience with the pneumococcal quinolone moxifloxacin. Expert Rev Anti Infect Ther 7:645–668

    Article  CAS  PubMed  Google Scholar 

  10. Bayer Healthcare (2015) Avelox–full prescribing information. http://labeling.bayerhealthcare.com/html/products/pi/Avelox_PI.pdf

  11. Moise PA, Birmingham MC, Schentag JJ (2000) Pharmacokinetics and metabolism of moxifloxacin. Drugs Today 36:229–244

    Article  CAS  PubMed  Google Scholar 

  12. Stass H, Dalhoff A, Kubitza D, Schühly U (1998) Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 42:2060–2065

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH (1999) Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 43:2793–2797

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Stass H, Kubitza D (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 43:83–90

    Article  CAS  PubMed  Google Scholar 

  15. Stass H, Kubitza D, Halabi A, Delesen H (2002) Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 53:232–237

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Stass H, Kubitza D, Möller JG, Delesen H (2005) Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Br J Clin Pharmacol 59:536–541

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. European Medicines Agency (2011) EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**—Guideline on bioanalytical method validation. European medicines agency, committee for medicinal products for human use (CHMP)

  18. Food and Drug Administration (2001) Guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research

  19. Beal SL, Sheiner LB (2013) Boeckmann AJ (1989-2013) NONMEM users guide. Icon Development Solutions, Ellicott City

    Google Scholar 

  20. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N (2005) PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241–257

    Article  PubMed  Google Scholar 

  21. Jonsson EN, Karlsson MO (1999) Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Progr Biomed 58:51–64

    Article  CAS  Google Scholar 

  22. Green B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–133

    Article  PubMed  PubMed Central  Google Scholar 

  23. DuBois D, DuBois EF (1916) A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med 17:863–871

    Article  CAS  Google Scholar 

  24. Imai E, Yasuda Y, Makino H (2011) Japan association of chronic kidney disease initiatives (J-CKDI). JMAJ 54:403–405

    Google Scholar 

  25. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17:2937–2944

    Article  PubMed  Google Scholar 

  26. Lee CS, Cha RH, Lim YH, Kim H, Song KH, Gu N, Yu KS, Lim CS, Han JS, Kim S, Kim YS (2010) Ethnic coefficients for glomerular filtration rate estimation by the modification of diet in renal disease study equations in the Korean population. J Korean Med Sci 25(11):1616–1625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266

    Google Scholar 

  28. Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U (2010) Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 88:643–651

    Article  CAS  PubMed  Google Scholar 

  29. Yafune A, Ishiguro M (1999) Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: a use of bootstrap standard error. Stat Med 18:581–599

    Article  CAS  PubMed  Google Scholar 

  30. Efron B, Tibshirani RJ (1993) An introduction into the bootstrap. Chapman & Hall, New York

    Book  Google Scholar 

  31. Holford N (2005) The visual predictive check—superiority to standard diagnostics (Rorschach) Plots. PAGE 14 Abstract 738. www.page-meeting.org/?abstract=738

  32. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481–504

    Article  CAS  PubMed  Google Scholar 

  33. Schwab D, Grauer M, Hahn EG, Mühldorfer S (2005) Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract. Aliment Pharmacol Ther 22:417–422

    Article  CAS  PubMed  Google Scholar 

  34. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095

    Article  CAS  PubMed  Google Scholar 

  35. Williams DA (1988) Drug metabolism. In: Principles of medicinal chemistry, 3rd eds. Foye, W.O. & Lea & Febiger pp 79-117 (Philadelphia)

  36. Hong T, Han S, Lee J, Jeon S, Park GJ, Park WS, Lim KS, Chung JY, Yu KS, Yim DS (2015) Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects. Drug Des Devel Ther 26:1233–1245

    Google Scholar 

  37. Klaassen CD, Boles JW (1997) Sulfation and sulfotransferases 5: the importance of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J 11:404–418

    Article  CAS  PubMed  Google Scholar 

  38. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751–790

    Article  CAS  PubMed  Google Scholar 

  39. Rowland IR, Mallett AK, Wise A (1985) The effect of diet on the mammalian gut flora and its metabolic activities. Crit Rev Toxicol 16:31–103

    Article  CAS  PubMed  Google Scholar 

  40. Mayorga RL, González VR, Cruz ASM, Melendez AA, Reyes CPA, Chavaro PDA, Ramos TI, Ramos IN, Rodríguez MMM, Langella P, Bermúdez HL, Azaola EA (2016) Correlation between diet and gut bacteria in a population of young adults. Int J Food Sci Nutr 67:470–478

    Article  Google Scholar 

  41. Nam YD, Jung MJ, Roh SW, Kim MS, Bae JW (2011) Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. PLoS ONE 6:1–15

    Google Scholar 

  42. Jung JY, Lee SH, Kim JM, Park MS, Bae JW, Hahn Y, Madsen EL, Jeon CO (2011) Metagenomic analysis of kimchi, a traditional Korean fermented food. Appl Environ Microbiol 77:2264–2274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by the Research on Regulatory Science of Pharmaceuticals and Medical Devices from the Japan Agency for Medical Research and Development (AMED).

Author information

Authors and Affiliations

  1. Laboratory of Clinical Pharmacokinetics, School of Pharmacy, Nihon University, Chiba, Japan

    M. Kaneko, T. Aoyama, Y. Ishida, A. Miyamoto & Y. Matsumoto

  2. Clinical Sciences Japan, Bayer Yakuhin Ltd, Osaka, Japan

    M. Kaneko

  3. Clinical Pharmacology Strategy, Japan Medical & Development, Bristol-Myers Squibb, Tokyo, Japan

    Y. Ishida

  4. Biochemistry and Immunochemistry, National Institute of Health Sciences, Tokyo, Japan

    Y. Saito

  5. Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan

    M. Tohkin

  6. Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Aichi, Japan

    M. Tohkin

  7. Department of Inflammation & Pain Control Research, Toho University School of Medicine, Tokyo, Japan

    S. Kawai

Authors
  1. M. Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Aoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Tohkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Matsumoto.

Ethics declarations

Conflict of interest

M. Kaneko is an employee of Bayer Yakuhin Ltd., although this author does not hold stock options in the company. The other authors declare no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaneko, M., Aoyama, T., Ishida, Y. et al. Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men. J Pharmacokinet Pharmacodyn 45, 199–214 (2018). https://doi.org/10.1007/s10928-017-9556-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-017-9556-7

Keywords

Search

Navigation